Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
What safety, toxicity, or tolerability evidence is attached?
Normalized for positional visualization, not a replacement for the reported modified notation.
CYFQNCPRG
Original notation retained for interpretation and comparison.
CYFQNCPRG
Interpretation: Evidence should be compared across compatible peptide identities and peptidoforms. A sequence-only match may not be equivalent when terminal modifications, stereochemistry, cyclization, or cross-links differ.
CYFQNCPRGPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
| Link | Method | Confidence | Match |
|---|---|---|---|
| Open |
| Feature | Positions | Interpretation | Link |
|---|---|---|---|
| Disulfide | 1-6 | 2.02 A SG-SG | Open |
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
Modeled net charge across common formulation and assay pH checkpoints.
Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.
Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.
Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.
Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.
A280 (1 g/L) ≈ 1.37 · 1,615 M⁻¹·cm⁻¹ with 1 disulfide
Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 0 % | Comparable | PepTherDia curated product PK field | Route: ORAL · 3 · Vasopressin (or Argipressin) · exact product name match · exact or normalized match | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 140 mL/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Vasopressin· 12.3 Pharmacokinetics · volume of distribution single · The volume of distri... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Serum/plasma stability and protease stability evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1.3 minutes 78 seconds | Comparable | Radioimmunoassay · Rabbit plasma | Dose/window: Endogenously administered · Proteases from Rabbit plasma · in vivo | Open |
| 2 | Observation 5.4(lower phase) | Reported | Radioimmunoassay · Rabbit plasma | Dose/window: Exogenously administered · Proteases from Rabbit plasma · in vivo | Open |
| 3 | Observation 0.9(fast component) | Reported | Radioimmunoassay · Rabbit plasma | Dose/window: Exogenously administered · Proteases from Rabbit plasma · in vivo | Open |
Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.
Reviewed observations retained without being collapsed into comparable values.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | range 9-25 mL/min/kg | Comparable | curated therapeutic product PK entry | Route: Official current-label support for vasopressin clearance in vasodilatory shock patients. | Open |
| 2 | 9-25 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Vasopressin· 12.3 Pharmacokinetics · clearance range direct · Elimination At infusion rat... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
PubMed 17684103 | Persistence Half Life | No reported alias CYFQNCPRGexact | 7 identity 7 evidence |
PubMed 2521208 | PersistenceStability Half Life, Serum Plasma Stability | No reported alias CYFQNCPRGexact | 4 identity 4 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYFQNCPRGexact | 4 identity 4 evidence |
DOI 10.1038/s41598-024-74188-9 | Exposure Area Under Curve, Max Concentration | No reported alias | 0 identity 7 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYFQNCPRGexact | 2 identity 2 evidence |
Reference link | DistributionPersistence Clearance, Plasma Protein Binding, Volume Of Distribution | No reported alias | 0 identity 3 evidence |
PubMed 7418787 | Persistence Half Life | No reported alias CYFQNCPRGexact | 1 identity 1 evidence |
PubMed 22186872 | Persistence Half Life | No reported alias CYFQNCPRGexact | 1 identity 1 evidence |
Reference link | Persistence Clearance | No reported alias CYFQNCPRGexact | 1 identity 1 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYFQNCPRGexact | 1 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0018357' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.
Features are shown only when a reported notation or topology record supports them.
Cysteine linkage reported between positions 1 and 6.
| Experimental structure match |
| experimental |
| 9 aa |
| Open | Experimental structure match | experimental | 9 aa |
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 7264 pg*min/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: endotracheal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| 2 | 675 pg*min/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| 3 | 2012 pg*min/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 958 pg/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: endotracheal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| 2 | 384 pg/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| 3 | 399 pg/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
| 4 | 2253 pg/mL | Comparable | ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma | Route: intravenous · Dose/window: baseline to 10 min post-dose serial arterial sampling | Open |
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IM, SC, IV, NASAL · 3 · Vasopressin (or Argipressin) · exact product name match · exact or normalized match | Open |
| 2 | Observation Distribution Vasopressin does not appear to bind plasma protein. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Vasopressin· 12.3 Pharmacokinetics · plasma binding no apparent binding text · Distributi... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 4.0 x 10^-5 cm/s | Comparable | (Co)-culture · blood-brain barrier | Pe · non saturable | Open |
| 2 | 0.00827 mL/g | Comparable | Capillary depletion · blood-brain barrier | CD (parenchyma/serum) · saturable | Open |
| 3 | 0.00237 mL/g/min | Comparable | In situ brain perfusion · blood-brain barrier | Kin · NA | Open |
| 4 | 0.0042 mL/g | Comparable | In situ brain perfusion · blood-brain barrier | Vi · NA | Open |
| 5 | 148 ratio | Comparable | Intracarotid injection · blood-brain barrier | Blood/brain ratio · NA | Open |
| 6 | 1.1 x 10^-4 mL/g/min | Comparable | Intravenous injection (multiple time regression) · blood-brain barrier | Kin · NA | Open |
| 7 | 142 | Reported | NA · NA · NA · blood-brain barrier | Route: Intracarotid injection · Permeability | Open |
| 8 | 148 | Reported | NA · NA · NA · blood-brain barrier | Route: Intracarotid injection · Permeability | Open |
| 9 | Observation raw_value: 0.0042 ml/g; result: 0.0042 ml/g; transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: in situ brain perfusion · Permeability | Open |
| 10 | Observation raw_value: 0.00237 mL/(g x min); result: 0.00237 mL/(g x min); transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: in situ brain perfusion · Permeability | Open |
cell monolayer
barrier evidence
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | > 7 days > 604800 seconds | Comparable | HPLC and LC/ITMS · Bacterial strain B-9 cell culture | Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro | Open |
| 2 | 3 minutes 180 seconds | Comparable | Radioimmunoassay · mouse · Insulin-treated IRAP-/- mice. | Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo | Open |
| 3 | 1 minutes 60 seconds | Comparable | Radioimmunoassay · mouse · Insulin-treated IRAP+/+ mice | Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo | Open |
| 4 | approx 1.5 minutes approx 90 seconds | Comparable | Radioimmunoassay · mouse · Saline treated IRAP+/+ mice | Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo | Open |
| 5 | Observation 47.4 (t1/2 of specific radioactivity) | Reported | Liquid scintillation spectrometer · Weakly acidic solution (pH 4.0, acetic acid) | Dose/window: 0.2 mg · in vitro | Open |
| 6 | Observation 1.06 ±0.19 (fast phase) | Reported | Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats | Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo | Open |
| 7 | Observation 5.96 ±0.58 (slow phase) | Reported | Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats | Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo | Open |
| 8 | Observation 1.00 ±0.15 (fast phase) | Reported | Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31260 | Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo | Open |
| 9 | Observation 8.90 ±0.37 (slow phase) | Reported | Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31261 | Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo | Open |
| 10 | Observation 80 (elimination t1/2 after 6-24h of i/v injection) | Reported | Radioimmunoassay, HPLC · (Dose i/v injected)urine of women with endometriosis | Dose/window: 500 μg/kg · Proteases from urine of women with endometriosis · in vivo | Open |
The identity reference does not expose a sequence string.
CYFQNCPRG
CYFQNCPRG
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.